Agios Pharmaceuticals (AGIO) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.09

Estimate

-$1.23

Surprise

+11.4%

Revenue (period 2026-09-30)

$55.4M

Score today

4.7/10

Revenue source: xbrl.

Agios Pharmaceuticals (AGIO) reported a narrower loss than forecast — adjusted EPS of -$1.09 against the -$1.23 estimate (a 11.4% beat on a still-unprofitable quarter).

• HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $62 — benzinga, 2026-11-06
• Agios Pharmaceuticals Q3 2026 Earnings Call Transcript — benzinga, 2026-11-05
• Agios Pharmaceuticals Reports Q3 2026 Financial Results and Operational Updates — fiscal.ai, 2026-11-05

TrendMatrix currently rates AGIO Sell at 4.7/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +11.4% surprise compares with a +5.1% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$29.23

Price target

$39.91

Stop

$27.18

Upside to target

+36.5%

Reward-to-risk

2.5:1

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.69B

P/E (fwd)

-7.0

52-week range

$22.24–$46.00

Off 52-week high

36.5%

RSI (14)

34

Volume vs avg

0.26×

Score today

4.7/10